MARS Bioimaging Ltd (MBI) was founded in 2007 to commercialize the cutting-edge Medipix technology and bring photon-counting CT to the clinic.
MBI has established itself as the world’s leading research and development group in spectral molecular imaging, and to-date has delivered the world’s first commercial pre-clinical spectral CT scanner.
The MARS Microlab 5X120 is based on the next generation of x-ray detectors (Medipix3RX) developed in collaboration with CERN, University of Canterbury, University of Otago, and other partners. Using our technology, customers can conduct experiments in a system that is directly translatable to human clinical imaging.
MBI works closely with customers to provide a wide range of spectral imaging solutions for applications ranging from cancer detection to development of novel contrast agents. Contact us to find out how MARS Microlab 5X120 can improve your research. Subject to regulatory approvals, MBI’s human extremity scanner will soon be available for clinical use.
Recent Awards
HealthTech Award for Best Translational Project – HealthTech Week 2019
Finalist in Best Hardware Product category – NZ Hi-Tech Awards 2018
Winner of Best Emerging New Zealand Innovation – New Zealand Innovations Award 2017
Winner of Best Innovation in Health and Science – New Zealand Innovations Award 2017
Winner of Supreme Award (Small Enterprise) – Champion Canterbury Business Awards 2017
Winner of Champion Innovations – Champion Canterbury Business Awards 2017
Winner of Champion Producer/Manufacturer (Small Enterprise) – Champion Canterbury Business Awards 2018
(transferred from MBI official website)